Pharma BD Deal Intelligence
Bayer's $300M bet on Direvo's antibody-engineering platform left no visible trace in its later pipeline, marketed portfolio, or biologics site strategy.
Full analysis, sources & comparables →Bayer HealthCare acquires DIREVO Biotech AG, whose high-throughput protein-engineering technology enables rapid discovery and optimization of…
Bayer HealthCare buys DIREVO Biotech, acquiring high-throughput protein-engineering technology for the discovery and optimization of biopharmaceuticals…
Bayer's purchase of Direvo strengthens biologics R&D and adds a Cologne center to complement its existing R&D hubs in Berlin, Wuppertal, and Berkeley.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Bayer HealthCare acquired German biotech Direvo Biotech AG for approximately EUR 210 million (roughly $300 million) in an all-cash deal, gaining a preclinical pipeline of therapeutic antibodies and proteases plus a high-throughput protein-engineering platform for biopharmaceutical discovery and optimization. The acquisition strengthened Bayer Schering Pharma's biologics R&D capabilities and added a Cologne research site alongside existing hubs in Berlin, Wuppertal, and Berkeley; Direvo's separate industrial-biotechnology subsidiary was excluded and sold separately.
Bayer's $300M bet on Direvo's antibody-engineering platform left no visible trace in its later pipeline, marketed portfolio, or biologics site strategy.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer HealthCare AG / Direvo Biotech AG (this deal) | 2008 | $300M | 31 |
| ViroPharma Incorporated / Lev Pharmaceuticals, Inc. | 2008 | $443M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Alkermes plc / Cephalon, Inc. (Vivitrol rights) | 2008 | $27M | 83 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
← Browse all deals · How we score deals
More: 2008 deals